Restoring Balance

At Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments. By inventing, developing and commercializing these next-generation therapies, we have one goal: to help patients lead healthier lives.

Who we do it for

Patients like Olivia are the reason we’re developing next-generation medicines

Whether we are looking to treat ocular surface diseases such as dry eye disease and allergic conjunctivitis or ultra-rare conditions such as Sjögren-Larsson Syndrome (SLS) and Proliferative Vitreoretinopathy (PVR), our goal is to help patients lead healthier lives. We accomplish this by developing novel medicines that target immune-mediated diseases.
Learn More About Immune-Mediated Diseases
A patient with Sjögren-Larsson Syndrome (SLS) gives an interview.
Our Science

Restoring Balance Utilizing Novel Mechanisms of Action

An estimated 7% of western society suffers from some form of immune-mediated disease. At Aldeyra, we are building a proprietary pipeline focused on three distinct mechanisms of action: Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase (DHFR) inhibition, and Chaperome (CHP) inhibitors to target immune-mediated ocular diseases and select systemic conditions.
Learn More
Scientist placing a sample under a microscope

Therapeutic Focus

Targeting Immune-Mediated Diseases with High Unmet Need

Brown eye with eye dropper

Ocular Diseases

We’re developing therapies for the treatment of dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy.

Read More About Ocular Disease Treatment

Woman holding healthcare provider’s hand

Systemic Diseases

We’re developing product candidates that can be administered orally or by injection to treat systemic disease.

Read More About Systemic Disease Treatment